Mobile Button

About Us

Business Model

At ENIMMUNE, our main business activity is to conduct clinical trials of new drugs, develop sales outlets, and collaborate with research-based pharmaceutical companies to facilitate the commercialization of new drugs. By forging an alliance within the ecosystem, we integrate all sources to roll out new drugs efficiently. The phased results of new drug development are also licensed to other manufacturers. In the future, we plan to introduce technology to develop innovative new drugs.

Mission & Vision

Upholding an idea that love is the starting point for everything meaningful, ENIMMUNE strives to take care of people through prevention and treatment. To protect people from diseases, we focus on the prevention and treatment of emerging infectious diseases in hopes of helping people live healthy and quality lives by facilitating the development of new drugs and vaccines.

Cooperating with the industry,
academia, and research institutions as well as clinical trial centers

Enimmune Corp. is a biologics research and marketing company jointly established by Adimmune Corporation and a venture capital firm. Upholding an idea that the pharmaceutical industry is a life-saving cause, we are actively developing new drugs and sales outlets.
We cooperate with world-renowned research institutions to develop new drugs for unmet medical needs through technology transfer, which can reduce the risk of R&D failure and increase the chance of success in clinical trials. We also maintain connections with domestic medical centers with rich experience in clinical trials. To speed up the launch of new drugs in the global arena, we expect to build a clinical trial platform with experts in cross-strait laws and regulations through international cooperation programs.

Working with world-renowned research institutions to obtain drug licenses and sales outlets

In the biotechnology industry, we are a company engaging in new drug development. To go beyond the academic research, our goal is to obtain drug licenses and control sales outlets for innovative or industrially valuable new drugs or proteins. After target validation, we proceed to conduct clinical trials and registration, so as to quickly commercialize them through the division of labor.

Speeding up new drug development through strategic alliances

ENIMMUNE engages in the development and clinical trials of new drugs, new drug applications, and marketing. We collaborate with research-based companies with high potential to facilitate commercialization of new drugs. The phased results of new drug development are also licensed to other manufacturers. As a player in the biotechnology industry, we operate at less risk based on an innovative business model. The key lies in the effective allocation of resources within the ecosystem through strategic alliances, which allows us to roll out new drugs efficiently.

to top